-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zectivimod in Atopic Dermatitis (Atopic Eczema)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zectivimod in Atopic Dermatitis (Atopic Eczema) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zectivimod in Atopic Dermatitis (Atopic Eczema) Drug Details: Zectivimod...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ganetespib in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ganetespib in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ganetespib in Peritoneal Cancer Drug Details: Ganetespib (STA-9090) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ganetespib in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ganetespib in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ganetespib in Fallopian Tube Cancer Drug Details: Ganetespib (STA-9090) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ganetespib in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ganetespib in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ganetespib in Epithelial Ovarian Cancer Drug Details: Ganetespib (STA-9090) is...
-
Product Insights
NewNet Present Value Model: Aldeyra Therapeutics Inc’s Methotrexate
Empower your strategies with our Net Present Value Model: Aldeyra Therapeutics Inc's Methotrexate report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Donafenib Tosylate in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Donafenib Tosylate in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Donafenib Tosylate in Esophageal Cancer Drug Details: Donafenib tosylate (Zepsun)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SHRA-1904 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SHRA-1904 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SHRA-1904 in Solid Tumor Drug Details: SHRA-1904 is under development for...
-
Product Insights
NewNet Present Value Model: Aldeyra Therapeutics Inc’s Reproxalap
Empower your strategies with our Net Present Value Model: Aldeyra Therapeutics Inc's Reproxalap report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Innovation Ranking
Innovation Ranking – Aldeyra Therapeutics Inc
Aldeyra Therapeutics Inc (Aldeyra Therapeutics), is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, an aldehyde trap for the treatment of allergic conjunctivitis and dry eye disease; ADX-2191 to treat proliferative vitreoretinopathy and intraocular lymphoma; and ADX-103/10X for the treatment of retinal disease. Aldeyra Therapeutics utilizes reactive aldehyde species (RASP), dihydrofolate reductase (DHFR) and chaperome (CHP) inhibition for advancing its pipeline products. The company’s drug candidates offer treatment for inflammation and genetic...
-
Product Insights
NewNet Present Value Model: Pfizer Inc’s Marstacimab
Empower your strategies with our Net Present Value Model: Pfizer Inc's Marstacimab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.